Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acucela and Otsuka Pharmaceutical have commenced a randomized, multi-center, investigator-masked, placebo- and active-controlled, dose-escalation Phase 1/2 clinical trial to investigate OPA-6566 in patients with open-angle glaucoma or ocular hypertension.
Subscribe to our email newsletter
Discovered by Otsuka, OPA-6566 is an ophthalmic solution indicated to reduce intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension patients
The trial aims to evaluate the safety, tolerability and the IOP-lowering effects of OPA-6566 in patients with open-angle glaucoma or ocular hypertension.
The trial will be conducted at clinical sites in the US.